Crescent Biopharma (CBIO) Return on Capital Employed (2014 - 2026)
Crescent Biopharma (CBIO) reported Return on Capital Employed of 79.38% for Q1 2026, up 16476.0% year-over-year from N/an in Q1 2025, and up 20.32% quarter-over-quarter from 99.62% in Q4 2025.
Crescent Biopharma (CBIO) Return on Capital Employed (2014 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 13 years of Return on Capital Employed data on file, last reported at 79.38% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 79.38%, up 16476.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 79.38% (up 16476.0% YoY), and the FY2025 annual result was 149.81%, down 2004.0% from the prior year.
- Return on Capital Employed climbed to 79.38% in Q1 2026 per CBIO's latest filing, from 99.62% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 61.41% in Q3 2025 and troughed at 257.39% in Q4 2024.
- A 5-year average of 119.38% and a median of 97.6% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed tumbled 16481 bps in 2024, then surged 16476 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 105.33% in 2022, then increased by 12 bps to 92.58% in 2023, then plunged by 178 bps to 257.39% in 2024, then surged by 61 bps to 99.62% in 2025, then rose by 20 bps to 79.38% in 2026.
- Business Quant data shows CBIO's Return on Capital Employed at 79.38% in Q1 2026, 99.62% in Q4 2025, and 61.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -79.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.38% |
| Dec 31, 2025 | -99.62% |
| Sep 30, 2025 | -61.41% |
| Jun 30, 2025 | -84.78% |
| Mar 31, 2025 | -244.14% |
| Dec 31, 2024 | -257.39% |
| Sep 30, 2024 | -214.12% |
| Jun 30, 2024 | -163.80% |
| Mar 31, 2024 | -114.46% |
| Dec 31, 2023 | -92.58% |
| Sep 30, 2023 | -78.85% |
| Jun 30, 2023 | -66.77% |
| Mar 31, 2023 | -81.46% |
| Dec 31, 2022 | -105.33% |
| Sep 30, 2022 | -102.75% |
| Jun 30, 2022 | -97.60% |
| Mar 31, 2022 | -84.96% |
| Dec 31, 2021 | -71.03% |
| Sep 30, 2021 | -57.83% |
| Jun 30, 2021 | -47.94% |